Overview

The Gene Technology Act 2000, enacted by the Parliament of Australia, establishes a regulatory framework designed to safeguard human health and the environment from potential risks associated with gene technology. This Act was introduced to address the need for a structured regulatory approach to the development and use of genetically modified organisms (GMOs) within Australia. The primary objective of the Act is to ensure that gene technology is managed in a way that minimises risks while facilitating innovation in the field. As part of this regulatory system, the Office of the Gene Technology Regulator (OGTR) is responsible for assessing applications for activities involving GMOs, including clinical trials of genetically modified viruses. The OGTR’s role is to evaluate the potential risks and benefits of proposed activities and to implement appropriate risk management measures to protect public health and the environment.

Scope and Application

The draft assessment for the clinical trial of a genetically modified virus for the treatment of liver cancer under the gene technology regulatory system applies to Clinical Network Services Pty Ltd (CNS), the entities conducting the trial, and the hospitals involved across Australia. The application, DIR 140, seeks to administer the genetically modified virus to up to 50 adult volunteers with advanced liver cancer as part of a Phase 3 clinical trial, which would be overseen by trained medical staff. The application aims to evaluate the safety and efficacy of the GM virus when used in conjunction with standard cancer treatments. The trial's geographic reach is national, involving multiple hospitals throughout Australia. The Regulator's assessment has determined that the trial poses negligible to low risk to human health and safety and the environment. The application process includes public consultation, with submissions on the Risk Assessment and Risk Management Plan (RARMP) accepted until 27 January 2016, to inform the decision on whether to issue a licence. The proposed licence conditions are intended to manage risks and limit the trial's scale and scope while restricting the spread and persistence of the genetically modified organism.

Key Provisions

The key provisions of the draft legislation revolve around the assessment and licensing of a clinical trial for a genetically modified (GM) virus intended for the treatment of liver cancer. Section 1 outlines the purpose of the regulatory system, which is to safeguard public health and the environment by managing the risks associated with gene technology (s1). The Gene Technology Regulator is tasked with evaluating the application for the clinical trial, and the main focus is on Licence Application DIR 140 submitted by Clinical Network Services Pty Ltd (CNS) (s2). CNS plans to administer the GM virus to up to 50 adult volunteers with advanced liver cancer, in combination with standard cancer treatments, directly into tumours by trained medical staff (s3). The proposed trial may involve hospitals across Australia and is expected to last up to five years, allowing for any necessary follow-up studies (s4). The legislation imposes several obligations on the parties involved, primarily focusing on the management and mitigation of risks. The Regulator must ensure that the proposed clinical trial is assessed thoroughly to determine its potential impact on human health and the environment. This involves reviewing the Risk Assessment and Risk Management Plan (RARMP) prepared by CNS (s5). The RARMP must detail how the risks will be managed and controlled, ensuring that the trial is conducted safely and responsibly. Furthermore, the clinical trial must adhere to the proposed licence conditions, which are designed to limit the scale and scope of the trial and prevent the spread and persistence of the GMO (s6). In terms of enforcement and consequences for non-compliance, the Act provides for penalties and legal repercussions. Any breach of the licence conditions or failure to comply with the regulatory requirements can result in civil or criminal penalties (s7). While the specific penalties are not detailed in the draft, the overarching regulatory framework ensures that there are significant consequences for non-compliance, aimed at enforcing the safe and responsible conduct of gene technology activities (s8). These penalties could include fines or other sanctions, reflecting the seriousness of ensuring public safety and environmental protection.